Company Filing History:
Years Active: 2022
Title: Heribert Arnhof: Innovator in Oncology Therapeutics
Introduction
Heribert Arnhof is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of oncology through his innovative research and development of pharmaceutical compounds. With a focus on CDK8/CDK19 inhibitors, his work aims to provide new treatment options for oncological diseases.
Latest Patents
Heribert Arnhof holds 2 patents that reflect his expertise in medicinal chemistry. His latest patents include:
1. **[1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors** - This invention encompasses compounds of formula (I) wherein the groups R to R, A, and q have the meanings given in the claims and specification. These compounds are utilized as inhibitors of CDK8/19, and they are formulated into pharmaceutical compositions for use as medicaments, particularly for the treatment and/or prevention of oncological diseases.
2. **Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors** - Similar to his first patent, this invention includes compounds of formula (I) with specific group definitions. These compounds also serve as inhibitors of CDK8/19 and are developed into pharmaceutical compositions aimed at treating and preventing oncological diseases.
Career Highlights
Heribert Arnhof is currently employed at Boehringer Ingelheim International GmbH, where he continues to advance his research in oncology. His work is characterized by a commitment to developing effective therapeutic agents that can significantly impact patient care.
Collaborations
Throughout his career, Arnhof has collaborated with esteemed colleagues such as Harald Engelhardt and Sebastian Carotta. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Heribert Arnhof's contributions to the field of oncology through his patented inventions demonstrate his dedication to improving treatment options for patients. His work at Boehringer Ingelheim International GmbH continues to pave the way for advancements in cancer therapeutics.